|
|
|
|
|
|
|
26.05.26 - 13:33
|
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting (GlobeNewswire EN)
|
|
|
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in adults with relapsing forms of multiple sclerosis (RMS) at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 27-29, 2026 in Charlotte, N.C. Abstracts are available on the CMSC website at http://www.mscare.org/2026 and data presentations are also available and can be accessed either on the 2026 CMSC meeting app or on TG's website at www.tgtherapeutics.com/publications. All TG data will be presented by the respective authors during the CMSC conference on Thursday, May 28th, 2026. Additional details of the presentation schedule can be found below....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.03.26 - 12:33
|
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis (GlobeNewswire EN)
|
|
|
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in people with highly active relapsing forms of multiple sclerosis (RMS). The article, authored by Hans-Peter Hartung, MD, of Heinrich Heine University Düsseldorf and colleagues, was published in Neurology and Therapy. The analysis evaluated efficacy outcomes in participants with highly active disease at baseline, defined as ≥2 relapses in the year prior and ≥1 gadolinium-enhancing (Gd+) T1 lesion at baseline. Results demonstrated statistically significant reductions in relapse rates and MRI activity, as well as significantly higher rates of no evidence of disease activity (NEDA-3), with BRIUMVI compared to teriflunomide. Additional details from the publication are included below....
|
|
|
|
|
02.03.26 - 13:06
|
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis (Business Wire)
|
|
|
– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock–
– Cash received supports Precision's expected cash runway through 2028 and strategic focus on in vivo gene editing pipeline –DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the achievement of a clinical milestone under its license agreement with TG Therapeutics, Inc. (Nasdaq: TGTX). The milestone payment for azercabtagene zapreleucel (azer-cel) was triggered by progress of a Phase 1 clinical trial of azer-cel in progressive forms of multiple sclerosis (MS). As a result of this milestone event, Precision will receive $7.5 million in proceeds, inclusive of $5.25 million cash and $2.25 million for the purchase of 201,504 shares of Precision common stock by TG Therapeutics at $11.17 per share, pursuant to the...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
